EUVIMEDEUVIMED entdecken
Crossref

Vascular disruption-triggered physiological cascade enables a therapeutic window for fibrin-hypoxia dual-targeting nanomedicines in solid tumors

Ya Liu, Jianlin Lv, Jincheng Du, Jiachong Chi, Kun Wang, Chenguang Yang, Lili Ma, Haiyang Yu, Kazuo Sakurai, Yajun Xu, Zhaohui Tang, Xuesi Chen

Journal of Controlled Release · 2026-07 · 395 · 115013

DOI: 10.1016/j.jconrel.2026.115013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-07. Verfasst von Ya Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, Chin…. Hauptthemen laut MEDLINE: Fibrin, Prodrugs, Antineoplastic Agents, Camptothecin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Jilin Provincial Key Research and Development Plan Project, National Natural Science Foundation of China, Jilin Provincial Science and Technology Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancing tumor selectivity remains a central challenge in cancer therapy, particularly for solid tumors with high heterogeneity. Herein, we report a novel drug delivery strategy that exploits the physiological cascade induced by tumor vascular disruption via vascular disrupting agents (VDAs) or surgery to create a transient therapeutic window characterized by local fibrin deposition and exacerbated hypoxia. We designed a dual-targeting nanoprodrug (FT11-AExT-NPs) consisting of a fibrin-binding FT11 peptide, a hypoxia-activated azo-linker, and the topoisomerase I inhibitor exatecan (ExT). This nanoprodrug selectively accumulates in tumors via fibrin targeting and releases active ExT specifically under hypoxic conditions. Using a triple-negative breast cancer 4T1 mouse model, we demonstrate that combination therapy with VDA and FT11-AExT-NPs increases the concentration of activated ExT in tumors by 31.7-fold compared to free prodrug, achieving 98.0% tumor suppression and a 66.7% cure rate. In a postoperative adjuvant setting, FT11-AExT-NPs leverages surgery-induced vascular disruption to reduce tumor recurrence by 50% through targeted eradication of residual tumor tissue. This strategy reduces reliance on tumor-specific biomarkers by exploiting treatment-induced fibrin deposition and hypoxia, and showed reduced systemic toxicity in the models tested.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrinProdrugsAntineoplastic AgentsCamptothecinTopoisomerase I InhibitorsPeptidesAnimalsFemaleCell Line, TumorMice, Inbred BALB CDrug Delivery SystemsHumansNanomedicineNanoparticlesMice

Stichwörter der Autor:innen

Drug deliveryHypoxia-activated prodrugNanomedicinesTopoisomerase I inhibitorTriple-negative breast cancerVascular disruption

Substanzen

FibrinProdrugsAntineoplastic AgentsCamptothecinTopoisomerase I InhibitorsPeptides

Autor:innen und Institutionen

  • State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China; School of Applied Chemistry and Engineering, University of Science…
  • Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, China.
  • Research Center for Drug Metabolism, School of Life Sciences, Jilin University, Changchun 130012, China.
  • State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
  • Department of Chemistry and Biochemistry, The University of Kitakyushu, 1-1 Hibikino, Kitakyushu 808-0135, Japan.
  • State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China. Electronic address: yjxu@ciac.ac.cn.

Förderung

  • Jilin Provincial Key Research and Development Plan Project
  • National Natural Science Foundation of China
  • Jilin Provincial Science and Technology Department
  • National Key Research and Development Program of China

Zitieren

APA

Liu, Y., Lv, J., Du, J., Chi, J., Wang, K., Yang, C., Ma, L., Yu, H., Sakurai, K., Xu, Y., Tang, Z., & Chen, X. (2026). Vascular disruption-triggered physiological cascade enables a therapeutic window for fibrin-hypoxia dual-targeting nanomedicines in solid tumors. Journal of Controlled Release, 395, 115013. https://doi.org/10.1016/j.jconrel.2026.115013

Vancouver

Liu Y, Lv J, Du J, Chi J, Wang K, Yang C, et al. Vascular disruption-triggered physiological cascade enables a therapeutic window for fibrin-hypoxia dual-targeting nanomedicines in solid tumors. Journal of Controlled Release. 2026;395:115013. doi:10.1016/j.jconrel.2026.115013

BibTeX
@article{Liu2026,
  author = {Liu, Ya and Lv, Jianlin and Du, Jincheng and Chi, Jiachong and Wang, Kun and Yang, Chenguang and Ma, Lili and Yu, Haiyang and Sakurai, Kazuo and Xu, Yajun and Tang, Zhaohui and Chen, Xuesi},
  title = {Vascular disruption-triggered physiological cascade enables a therapeutic window for fibrin-hypoxia dual-targeting nanomedicines in solid tumors},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {395},
  pages = {115013},
  doi = {10.1016/j.jconrel.2026.115013}
}
Kostenlos starten →